The research reported in this issue of the journal was funded by the HTA programme as project number 10/136/01. The contractual start date was in April 2012. The draft report began editorial review in October 2013 and was accepted for publication in April 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report. Acknowledgements We thank l the people recruited from the local UCAN for p...
CONTEXT: The incidence of localised prostate cancer is increasing worldwide. In light of recent evid...
Background The first histology-independent marketing authorisation in Europe was granted in 2019....
Acknowledgements This project was funded by the National Institute for Health Research (NIHR) [Cochr...
BACKGROUND: For people with localised prostate cancer, active treatments are effective but have sign...
Background: For people with localised prostate cancer, active treatments are effective but have sign...
Objective To analyse the evidence base for primary FT for localised PCa via a systematic review (SR...
This report The research reported in this issue of the journal was funded by the HTA programme as pr...
Background Prostate cancer (PCa) is the most common cancer in men in the UK. Patients with intermedi...
We would like to thank Aurea Martin for her writing assistance, proofreading, manuscript editing and...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
The authors are grateful to the following individuals and organisations for the following contributi...
Background: Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cau...
Funded by The National Institute for Health Research Health Technology Assessment programme.Peer rev...
This is the final version of the article. Available from NIHR Health Technology Assessment Programme...
Background: Evaluation of treatment options for localized prostate cancer (PCa) remains among the hi...
CONTEXT: The incidence of localised prostate cancer is increasing worldwide. In light of recent evid...
Background The first histology-independent marketing authorisation in Europe was granted in 2019....
Acknowledgements This project was funded by the National Institute for Health Research (NIHR) [Cochr...
BACKGROUND: For people with localised prostate cancer, active treatments are effective but have sign...
Background: For people with localised prostate cancer, active treatments are effective but have sign...
Objective To analyse the evidence base for primary FT for localised PCa via a systematic review (SR...
This report The research reported in this issue of the journal was funded by the HTA programme as pr...
Background Prostate cancer (PCa) is the most common cancer in men in the UK. Patients with intermedi...
We would like to thank Aurea Martin for her writing assistance, proofreading, manuscript editing and...
Context: Current evidence-based management for clinically localised prostate cancer includes active ...
The authors are grateful to the following individuals and organisations for the following contributi...
Background: Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cau...
Funded by The National Institute for Health Research Health Technology Assessment programme.Peer rev...
This is the final version of the article. Available from NIHR Health Technology Assessment Programme...
Background: Evaluation of treatment options for localized prostate cancer (PCa) remains among the hi...
CONTEXT: The incidence of localised prostate cancer is increasing worldwide. In light of recent evid...
Background The first histology-independent marketing authorisation in Europe was granted in 2019....
Acknowledgements This project was funded by the National Institute for Health Research (NIHR) [Cochr...